Stock Price Movement and Market Context
On 22 January 2026, Vivimed Labs’ stock recorded a day change of -4.89%, underperforming its sector by 6.05%. This decline extended a losing streak that has now lasted 21 consecutive trading days, during which the stock has depreciated by approximately 70.76%. The current price is notably below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling persistent bearish momentum.
The stock’s 52-week high was ₹24.01, but recent trading has seen it fall well below this level, reaching its lowest point in the past year. This contrasts with broader market trends, where the Sensex opened higher at 82,459.66 points on the same day, gaining 0.67%, although it was trading slightly lower at 82,270.40 points later in the session. The Sensex remains 4.73% below its own 52-week high of 86,159.02, and has experienced a three-week consecutive decline of 4.07%. Meanwhile, mid-cap stocks have shown relative strength, with the BSE Mid Cap index gaining 1.21%.
Financial Performance and Fundamental Indicators
Vivimed Labs’ financial metrics reveal several areas of concern. The company has not declared results in the last six months, contributing to uncertainty around its current financial position. Its long-term fundamental strength is rated weak, reflected in a low Mojo Score of 24.0 and a Mojo Grade of Strong Sell as of 22 December 2025, a new rating following a previous status of Not Rated.
The company’s ability to service debt is limited, with a high Debt to EBITDA ratio of 12.57 times, indicating significant leverage. The debt-equity ratio stands at 9.60 times, one of the highest levels recorded in the recent half-year period. This elevated leverage raises questions about the company’s financial flexibility and risk profile.
Profitability metrics also highlight challenges. The average Return on Equity (ROE) is a modest 1.75%, signalling low returns generated on shareholders’ funds. The company reported a negative Profit After Tax (PAT) of ₹-281.57 crores in the half-year ending June 2023, representing a decline of 34.93% compared to previous periods. Additionally, the debtors turnover ratio is low at 2.44 times, suggesting inefficiencies in receivables management.
Just made the cut! This Mid Cap from the Heavy Electrical Equipment sector entered our elite Top 1% list recently. Discover it before the crowd catches on!
- - Top-rated across platform
- - Strong price momentum
- - Near-term growth potential
Comparative Performance and Valuation
Over the past year, Vivimed Labs has generated a return of 0.00%, significantly lagging behind the Sensex’s 7.68% gain over the same period. The stock’s valuation appears risky relative to its historical averages, reflecting investor caution amid the company’s financial difficulties. Profitability has deteriorated sharply, with profits falling by 267.9% year-on-year, further weighing on sentiment.
The company’s market capitalisation grade is rated 4, indicating a relatively modest market cap compared to peers. This, combined with the weak fundamental scores and recent price action, has contributed to the stock’s strong sell rating by MarketsMOJO.
Sector and Market Environment
While Vivimed Labs faces headwinds, the broader market environment presents a mixed picture. The Sensex, despite recent declines, remains near its 52-week high, supported by mid-cap stocks which have outperformed in recent sessions. This divergence highlights the specific challenges faced by Vivimed Labs, which are not reflective of the overall market trend.
Investors monitoring the stock will note the extended period of price weakness and the absence of recent financial disclosures, which contribute to the cautious stance reflected in the company’s ratings and market performance.
Why settle for Vivimed Labs? SwitchER evaluates this micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Summary of Key Metrics
To summarise, Vivimed Labs’ stock has reached a 52-week low amid a prolonged decline spanning 21 trading days and a cumulative loss exceeding 70%. The company’s financial indicators point to elevated leverage, subdued profitability, and a lack of recent financial disclosures, all contributing to a cautious market outlook. The stock’s Mojo Grade of Strong Sell and a low Mojo Score of 24.0 reflect these concerns.
Despite broader market gains and mid-cap strength, Vivimed Labs remains under pressure, trading below all major moving averages and showing no signs of immediate recovery in price action. The company’s high debt levels and negative earnings growth continue to weigh on its valuation and investor sentiment.
Conclusion
Vivimed Labs’ recent fall to its 52-week low encapsulates a challenging period marked by financial strain and market underperformance. The stock’s extended losing streak and weak fundamental metrics highlight the difficulties faced by the company in maintaining investor confidence. While the broader market environment shows pockets of strength, Vivimed Labs remains a notable outlier with significant headwinds reflected in its share price and ratings.
Upgrade at special rates, valid only for the next few days. Claim Your Special Rate →
